Company behind innovative blood filtration device to receive legal advice to take product to market
George Frodsham, inventor of MediSieve
MediSieve has been announced winner of the CMS Healthcare Startup of the Year Award 2017 in the Beanstalks Competition .
This news was announced at the GIANT Health Event held at the Old Truman Brewery in London recently
The prestigious award, now in its second year, was given to the start-up medical company for itys advances in magnetic blood filtration.
The Beanstalk Awards are a competition for start-up companies with ideas, prototypes or advancements in the medical sector.
The awards aim to celebrate, encourage and reward innovation within the medical sector, where entrepreneurs are making great strides towards actionable advances in technology in order to tackle some of our biggest diseases and conditions we are facing in today's world.
Following its nomination for the TCT Magazine Awards 2017 in the Healthcare Application category; the latest award will enable MediSieve to expand business.
As a reward for winning the prestigious prize, the company is entitled to a package of legal services which are worth anything up to the value of £8,000 and provided by CMS. This will be tailored to the company's needs and will allow it to develop in any legal area from the development of new technology and patents through to commercial contracts and share schemes.
George Frodsham, founder and chief executive of MediSieve, said: "It's an amazing achievement and we're all happy to have won the award.
”Everyone has worked incredibly hard on our magnetic blood filtration device and it's great to see all that work and the future applications being recognised.
”We're still working on ways to improve the device to be able to broaden its applications and help to tackle some of the challenges that affect us all".”
The MediSieve device, an innovative medical blood-filtration device that magnetically filters particles from the bloodstream, is still undergoing extensive testing and research to be able to target the causes of specific diseases, such as sepsis and leukaemia and is hoped to be able to improve treatments for cases of malaria.